Quanterix Appoints New Director to Board
Ticker: QTRX · Form: 8-K · Filed: Apr 12, 2024 · CIK: 1503274
| Field | Detail |
|---|---|
| Company | Quanterix Corp (QTRX) |
| Form Type | 8-K |
| Filed Date | Apr 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, governance
TL;DR
Quanterix adds Dr. Paul J. Provost to its board, effective April 8, 2024.
AI Summary
Quanterix Corporation announced on April 8, 2024, a change in its board of directors. Specifically, Dr. Paul J. Provost has been appointed as a new director, effective immediately. This appointment is part of the company's ongoing governance and strategic direction.
Why It Matters
The addition of a new director can signal strategic shifts or a focus on specific expertise, potentially impacting the company's future direction and shareholder value.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.
Key Players & Entities
- Quanterix Corporation (company) — Registrant
- Dr. Paul J. Provost (person) — Newly appointed director
- April 8, 2024 (date) — Effective date of appointment
FAQ
Who is Dr. Paul J. Provost and what is his background?
The filing does not provide specific details about Dr. Provost's background, only that he has been appointed as a director.
What is the effective date of Dr. Provost's appointment?
Dr. Paul J. Provost's appointment is effective as of April 8, 2024.
What is Quanterix Corporation's principal executive office address?
Quanterix Corporation's principal executive offices are located at 900 Middlesex Turnpike, Billerica, MA 01821.
What is Quanterix Corporation's telephone number?
Quanterix Corporation's telephone number is (617) 301-9400.
What is the SIC code for Quanterix Corporation?
The Standard Industrial Classification (SIC) code for Quanterix Corporation is 3826, which corresponds to Laboratory Analytical Instruments.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2024-04-12 17:00:14
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share QTRX The Nasdaq G
Filing Documents
- tm2411565d1_8k.htm (8-K) — 28KB
- tm2411565d1_ex10-1.htm (EX-10.1) — 44KB
- tm2411565d1_ex10-2.htm (EX-10.2) — 47KB
- tm2411565d1_ex10-1img001.jpg (GRAPHIC) — 19KB
- tm2411565d1_ex10-2img001.jpg (GRAPHIC) — 19KB
- 0001104659-24-046830.txt ( ) — 362KB
- qtrx-20240408.xsd (EX-101.SCH) — 3KB
- qtrx-20240408_lab.xml (EX-101.LAB) — 33KB
- qtrx-20240408_pre.xml (EX-101.PRE) — 22KB
- tm2411565d1_8k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b)On April 8, 2024, Quanterix Corporation (the "Company") received notice from director Laurie Olson that she will not stand for re-election at the Company's 2024 Annual Meeting of Stockholders, which is expected to be held on June 3, 2024. Ms. Olson's decision not to stand for re-election was not because of any disagreement with the Company on any matter relating to its operations, policies or practices. (e) On April 9, 2024, the Company entered into an amendment to the Amended and Restated Employment Agreement, dated April 25, 2022, with Masoud Toloue , the Company's President and Chief Executive Officer. The amendment increases his salary continuation benefit from 12 months to 24 months if he is terminated without cause or if he resigns for good reason within the 90-day period immediately preceding or the twelve-month period immediately following a change-in-control of the Company. On April 11, 2024, the Company entered into an amendment to the Employment Agreement, dated August 3, 2023, with Vandana Sriram, the Company's Chief Financial Officer. The amendment increases her salary continuation benefit and health insurance continuation benefit from six months to twelve months and changes her bonus entitlement to her target bonus instead of her pro-rated target bonus if she is terminated without cause or if she resigns for good reason within the 90-day period immediately preceding or the twelve-month period immediately following a change-in-control of the Company.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment, dated April 9, 2024, to the Amended and Restated Employment Agreement, dated April 25, 2022, between the Registrant and Dr. Masoud Toloue 10.2 Amendment,effective as of April 11, 2024, to the Employment Agreement, dated August 3, 2023, between the Registrant and Vandana Sriram 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. QUANTERIX CORPORATION By: /s/ Vandana Sriram Vandana Sriram Chief Financial Officer Date: April 12, 2024